How We Deliver Best In Class solutions

Our focus on targeting metabolites allow us to diagnose chronic disease effectively

Addressing Unmet Needs

Innovative testing, a strong R&D pipeline, and an extensive patent portfolio makes our products unique

Advanced Technology

Allowing us the ability to deep profile key disease pathways, provide robust biomarker selection, and access to critical clinical resources

Experienced Team

With backgrounds in critical biomarker discoveries, our team brings decades of experience in building diagnostic solutions paired with an experienced laboratory management team

Metabolite Biomarker Assay Development

Our Approach

Precion specializes in the development, validation, and profiling of LC-MS/MS based small molecule biomarker assays.

Predeveloped Multiplexed Metabolite Biomarker Panels

Our predeveloped panels:

  • Fill the gap of metabolomics by including panels for non-detected metabolites like steroid hormones
  • Accurate and precise data, every time, with our capability to develop internal standards based on the area of ratio of samples
  • Absolute quantitation allowing for accurate comparability among studies

  • Trace analysis requiring only a small sample size

Offering Custom Metabolite Biomarker Assays

With decades of experience, the Precion team has developed biomarker assays covering hundreds of metabolites.

  • Assay development of custom biomarker panels

  • Fit-for-purpose-method validation
  • Sample analysis
  • Cost effective development providing the highest data in value

What sets our assays apart

Existing metabolomics companies are conceptually different from Precion. By using relative quantitation methods, competitors are lacking sensitivity and accuracy.

We hit the target every time

Using absolute quantitative methods:

  • Proper calibration curves used for every analyte

  • An internal standard for each analyte measured provides maximum accuracy

  • Our team specializes in LC-MS/MS, allowing any issues to be easily resolved creating efficient results and accurate data

  • Cost effective development providing the highest data in value

A Focus on Metabolites

Precion’s method, a metabolite based test, reveals what is actually happening.

Whereas a molecular based test used by competitors only shows what might be happening.

Chronic diseases are driven by genetic and non genetic factors that can make them difficult to diagnose on other platforms.

These factors include:

  • Diet
  • Exercise
  • Medication
  • Genetics
  • Microbiome

Our focus on targeting metabolites allows us to diagnose chronic diseases effectively.

DIET
EXERCISE
GENETICS
MEDICATION
MICROBIOME

Product Development Process

Our Process

Our team overcomes any challenges in LC-MS/MS based biomarker panel development with our unique approach built off quantitative analysis.

1

Biomarker Discovery

  • Metabolomics Screening

  • Lipidomics Screening – subset small molecules

  • Literature Data – our team identifies biomarkers that have been validated through decades of research

2

Biomarker Confirmation

  • Statistical analysis is performed on discovery data

  • Discovery is validated using complex multiplexed LC-MS/MS assays

3

Biomarker Application

  • Data is analyzed again to determine if biomarker is stable

  • A production assay is developed and applications include:

    • diagnostic testing
    • drug development
    • bioreactor monitoring

Fill out our project request form

Gold Standard Equipment

Technology

We use gold standard equipment for sample prep, analysis, storage, and synthesis.

Sample Preparation

  • Equipped for PP, LLE, SPE
  • Automated liquid handling
  • 96-well format sample processing

 

Low volume sample required

LC-MS/MS

  • Sciex Triple Quad 5500+ 
  • Sciex Triple Quad 7500+
  • coupled to Exion UHPLC for fast run times and difficult chromatographic separations

Ability to deep profile key disease pathways

Storage & Synthesis

  • Sample Storage at -20°C, -80°C
  • Equipment for small scale synthesis

Stable Labelled Internal Standards

Metabolite Biomarker Selections

Learn More About our Solutions

Offering Diagnostic product development and screening suited to your needs.

Request a
Custom Panel

Current Panel
Offerings

Panels in Clinical
Development

Contact Us

Dedicated, Passionate, Pioneers

Team

Our team overcomes any challenges in LC-MS/MS based biomarker panel development with our unique approach built off qualitative analysis.

Shaun Lonergan

Chief Executive Officer

His past experiences include commercialization of several major research and diagnostic instrument platforms. Mr. Lonergan participated in or led successful sale or public offering of several companies while holding senior management positions at Boehringer Mannheim (Roche), Perceptive Biosystems (Thermo), Third Wave Technologies (Hologic), NimbleGen (Roche), 454 Life Sciences (Roche), Ibis Biosciences (Abbott Molecular) and Seegene, Inc. He served as CEO of Nerites Corporation (DSM), attaining more than $7 million in grant awards and sale of the company to DSM. Mr. Lonergan earned his Master of Science degree in microbiology from the University of Rhode Island.

Klaus-Peter Adam

Chief Technology Officer

He received his Ph.D. at the Department of Pharmacognosy and Analytical Phytochemistry from the University of Saarland, Germany. Dr. Adam’s career spans three decades in various research and management positions in the field of
natural products analytics, biosynthesis, and bioanalysis of drugs in academia and industry at the University of Saarland, the Institute of Biological Chemistry at Washington State University, Cedra Corporation and Metabolon Inc.

Jim Klein

Chief Financial Officer

Jim Klein has served as a CFO for over 30 years with both private and public companies and has raised over $750 million for companies. He started his career with Price Waterhouse and transitioned to the private sector, holding positions of increasing responsibility, including serving as CFO of Triangle Pharmaceuticals where he led the company to a successful IPO. He has international experience with both public and nonpublic companies in the life science sector. He earned his Bachelor of Accountancy at the University of Mississippi and completed executive management programs at the London Business School, the Fuqua School of Business at Duke University, and the Kenan-Flagler Business School at the University of North Carolina.

Dedicated, Passionate, Pioneers

Scientific Advisors

Our management team is supported by a strong panel of advisory members with complementary experience

John Todd

  • OXFORD UNIVERSITY Welcome Trust Centre for Human Genetics – Director
  • CAMBRIDGE UNIVERSITY Royal Society – Fellow Medical Science Society- Fellow
  • Royal College of Physicians – Fellow
  • Minkowski Award
  • EASD-Novo Award

Jessica Lasky-Su

  • HARVARD MEDICAL SCHOOL Brigham and Women’s Hospital
  • President of Metabolomic Society
  • Scholar Award – Brigham Research Institute

Garth Ehrlich

  • DREXEL UNIVERSITY – Chaired Professor / Executive Director
  • UPMC – Founder of Clinical Molecular Diagnostics
  • CLIA LAB EXPERT – COVID19 and Genomic Medicine
  • Journal of Genetic Testing and Molecular Biomarker – Editor

John Todd

  • OXFORD UNIVERSITY Welcome Trust Centre for Human Genetics – Director
  • CAMBRIDGE UNIVERSITY Royal Society – Fellow Medical Science Society- Fellow
  • Royal College of Physicians – Fellow
  • Minkowski Award
  • EASD-Novo Award

Jessica Lasky-Su

  • HARVARD MEDICAL SCHOOL Brigham and Women’s Hospital
  • President of Metabolomic Society
  • Scholar Award – Brigham Research Institute

Garth Ehrlich

  • DREXEL UNIVERSITY – Chaired Professor / Executive Director
  • UPMC – Founder of Clinical Molecular Diagnostics
  • CLIA LAB EXPERT – COVID19 and Genomic Medicine
  • Journal of Genetic Testing and Molecular Biomarker – Editor

Contact Us Today

Partner with Precion and let our team develop your next superior assay.